{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:36:30Z","timestamp":1771018590432,"version":"3.50.1"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T00:00:00Z","timestamp":1613779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H06095"],"award-info":[{"award-number":["17H06095"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16H01881"],"award-info":[{"award-number":["16H01881"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003382","name":"CREST","doi-asserted-by":"publisher","award":["A3A28043"],"award-info":[{"award-number":["A3A28043"]}],"id":[{"id":"10.13039\/501100003382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Orexins\/hypocretins are hypothalamic neuropeptides that promote and stabilize wakefulness by binding to the orexin receptor type-1 (OX1R) and type-2 (OX2R). Disruption of orexinergic signaling results in the sleep disorder narcolepsy in mice, rats, dogs, and humans. The orexin receptor antagonist suvorexant promotes sleep by blocking both OX1R and OX2R. Whereas suvorexant has been clinically approved for the treatment of insomnia because it is well tolerated in experimental animals as well as in human patients, a logical question remains as to why orexin receptor antagonists do not induce overt narcolepsy-like symptoms. Here we show that acute and chronic suvorexant promotes both rapid eye movement (REM) and non-rapid eye movement (NREM) sleep without inducing cataplexy in mice. Interestingly, chronic suvorexant increases OX2R mRNA and decreases orexin mRNA and peptide levels, which remain low long after termination of suvorexant administration. When mice are chronically treated with suvorexant and then re-challenged with the antagonist after a 1-week washout, however, cataplexy and sleep-onset REM (SOREM) are observed, which are exacerbated by chocolate administration. Heterozygous orexin knockout mice, with lower brain orexin levels, show cataplexy and SOREM after acute suvorexant administration. Furthermore, we find that acute suvorexant can induce cataplexy and SOREM in wild-type mice when co-administered with chocolate under stress-free (temporally anesthetized) conditions. Taken together, these results suggest that suvorexant can inhibit orexin synthesis resulting in susceptibility to narcolepsy-like symptoms in mice under certain conditions.<\/jats:p>","DOI":"10.1093\/sleep\/zsab043","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T20:58:47Z","timestamp":1613854727000},"source":"Crossref","is-referenced-by-count":17,"title":["Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice"],"prefix":"10.1093","volume":"44","author":[{"given":"Mahesh K","family":"Kaushik","sequence":"first","affiliation":[{"name":"International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba , Tsukuba , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Aritake","sequence":"additional","affiliation":[{"name":"International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba , Tsukuba , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-8193","authenticated-orcid":false,"given":"Yoan","family":"Cherasse","sequence":"additional","affiliation":[{"name":"International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba , Tsukuba , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Imanishi","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Akita University Graduate School of Medicine , Akita , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kanbayashi","sequence":"additional","affiliation":[{"name":"International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba , Tsukuba , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Urade","sequence":"additional","affiliation":[{"name":"International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba , Tsukuba , Japan"},{"name":"Isotope Science Center, The University of Tokyo , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba , Tsukuba , Japan"},{"name":"Department of Molecular Genetics, University of Texas Southwestern Medical Center at Dallas , Dallas, TX"},{"name":"Life Science Center, Tsukuba Advanced Research Alliance, University of Tsukuba , Tsukuba , Japan"},{"name":"R&D Center for Frontiers of MIRAI in Policy and Technology, University of Tsukuba , Tsukuba , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,20]]},"reference":[{"key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"issue":"19","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1523\/JNEUROSCI.0073-14.2014","article-title":"Conditional ablation of orexin\/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function","volume":"34","author":"Tabuchi","year":"2014","journal-title":"J Neurosci"},{"issue":"4","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell"},{"issue":"18","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1523\/JNEUROSCI.5560-03.2004","article-title":"Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat","volume":"24","author":"Beuckmann","year":"2004","journal-title":"J Neurosci"},{"issue":"9197","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy","volume":"355","author":"Nishino","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat Med"},{"issue":"3","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"issue":"27","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.conb.2013.04.007","article-title":"Orexin deficiency and narcolepsy","volume":"23","author":"Sakurai","year":"2013","journal-title":"Curr Opin Neurobiol"},{"issue":"28","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1523\/JNEUROSCI.0586-04.2004","article-title":"Behavioral state instability in orexin knock-out mice","volume":"24","author":"Mochizuki","year":"2004","journal-title":"J Neurosci"},{"key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1749-6632.2010.05513.x","article-title":"The orexin system: roles in sleep\/wake regulation","volume":"1200","author":"Sakurai","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm1544","article-title":"Promotion of sleep by targeting the orexin system in rats, dogs and humans","volume":"13","author":"Brisbare-Roch","year":"2007","journal-title":"Nat Med"},{"issue":"6","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/clpt.2011.370","article-title":"Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial","volume":"91","author":"Hoever","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2202-15-109","article-title":"Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators","volume":"15","author":"Gotter","year":"2014","journal-title":"BMC Neurosci"},{"issue":"21","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","article-title":"Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder","volume":"94","author":"Zammit","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40265-020-01276-1","article-title":"Lemborexant: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pharmtox-010716-104837","article-title":"The discovery of suvorexant, the first orexin receptor drug for insomnia","volume":"57","author":"Coleman","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"2023031318062063600_","first-page":"259","article-title":"Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men","volume":"36","author":"Sun","year":"2013","journal-title":"Sleep"},{"issue":"1\u20132","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/01677063.2011.566953","article-title":"Promotion of sleep by suvorexant - a novel dual orexin receptor antagonist","volume":"25","author":"Winrow","year":"2011","journal-title":"J Neurogenet"},{"issue":"5","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"issue":"2","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"3","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5665\/sleep.2442","article-title":"Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy","volume":"36","author":"Black","year":"2013","journal-title":"Sleep"},{"issue":"6","key":"2023031318062063600_","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz302","article-title":"Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice","volume":"43","author":"Mahoney","year":"2019","journal-title":"Sleep"},{"issue":"22","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.1700499114","article-title":"Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models","volume":"114","author":"Irukayama-Tomobe","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1073\/pnas.1722686115","article-title":"Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy","volume":"115","author":"Kaushik","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1523\/JNEUROSCI.3906-15.2016","article-title":"An adenosine-mediated glial-neuronal circuit for homeostatic sleep","volume":"36","author":"Bjorness","year":"2016","journal-title":"J Neurosci"},{"issue":"6","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ana.23968","article-title":"Greatly increased numbers of histamine cells in human narcolepsy with cataplexy","volume":"74","author":"John","year":"2013","journal-title":"Ann Neurol"},{"issue":"8","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1460-9568.2008.06397.x","article-title":"Orexin B\/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons","volume":"28","author":"Borgland","year":"2008","journal-title":"Eur J Neurosci"},{"issue":"19","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"10911","DOI":"10.1073\/pnas.96.19.10911","article-title":"Orexin A activates locus coeruleus cell firing and increases arousal in the rat","volume":"96","author":"Hagan","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.neuroscience.2009.04.007","article-title":"Feeding-elicited cataplexy in orexin knockout mice","volume":"161","author":"Clark","year":"2009","journal-title":"Neuroscience"},{"issue":"23","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1523\/JNEUROSCI.0499-13.2013","article-title":"Role of the medial prefrontal cortex in cataplexy","volume":"33","author":"Oishi","year":"2013","journal-title":"J Neurosci"},{"issue":"3","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0306-4522(94)90174-0","article-title":"Cholinergic mechanisms in canine narcolepsy-II. Acetylcholine release in the pontine reticular formation is enhanced during cataplexy","volume":"59","author":"Reid","year":"1994","journal-title":"Neuroscience"},{"issue":"9560","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","article-title":"Narcolepsy with cataplexy","volume":"369","author":"Dauvilliers","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-08874-2","article-title":"Octacosanol restores stress-affected sleep in mice by alleviating stress","volume":"7","author":"Kaushik","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0896-6273(03)00330-1","article-title":"Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes","volume":"38","author":"Willie","year":"2003","journal-title":"Neuron"},{"issue":"2","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","article-title":"Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity","volume":"30","author":"Hara","year":"2001","journal-title":"Neuron"},{"key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.yrtph.2017.03.006","article-title":"Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant","volume":"86","author":"Born","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"issue":"90","key":"2023031318062063600_","first-page":"1","article-title":"The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold","volume":"14","author":"Gotter","year":"2013","journal-title":"BMC Neurosci"},{"key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fnbeh.2014.00182","article-title":"Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs","volume":"8","author":"Tannenbaum","year":"2014","journal-title":"Front Behav Neurosci"},{"issue":"12","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.5665\/sleep.2232","article-title":"The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors","volume":"35","author":"Mang","year":"2012","journal-title":"Sleep"},{"issue":"19","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1523\/JNEUROSCI.0080-14.2014","article-title":"GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy","volume":"34","author":"Black","year":"2014","journal-title":"J Neurosci"},{"issue":"7","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40261-018-0650-4","article-title":"Safety, tolerability, and pharmacokinetics of suvorexant: a randomized rising-dose trial in healthy men","volume":"38","author":"Yee","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"3","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/sleep\/29.3.295","article-title":"Diurnal variation in CSF orexin-A in healthy male subjects","volume":"29","author":"Grady","year":"2006","journal-title":"Sleep"},{"issue":"6","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"e0178573","DOI":"10.1371\/journal.pone.0178573","article-title":"Diurnal fluctuation in the number of hypocretin\/orexin and histamine producing: implication for understanding and treating neuronal loss","volume":"12","author":"McGregor","year":"2017","journal-title":"PLoS One"},{"issue":"38","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"12642","DOI":"10.1523\/JNEUROSCI.2120-10.2010","article-title":"Orexin directly excites orexin neurons through orexin 2 receptor","volume":"30","author":"Yamanaka","year":"2010","journal-title":"J Neurosci"},{"key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2013.00057","article-title":"Differential roles of orexin receptors in the regulation of sleep\/wakefulness","volume":"4","author":"Mieda","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ana.24019","article-title":"Increase of histaminergic tuberomammillary neurons in narcolepsy","volume":"74","author":"Valko","year":"2013","journal-title":"Ann Neurol"},{"issue":"15","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1523\/JNEUROSCI.4065-15.2017","article-title":"GABAergic neurons of the central amygdala promote cataplexy","volume":"37","author":"Mahoney","year":"2017","journal-title":"J Neurosci"},{"issue":"17","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"E3526","DOI":"10.1073\/pnas.1614552114","article-title":"Serotonin neurons in the dorsal raphe mediate the anticataplectic action of orexin neurons by reducing amygdala activity","volume":"114","author":"Hasegawa","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"9734","DOI":"10.1523\/JNEUROSCI.5632-12.2013","article-title":"Amygdala lesions reduce cataplexy in orexin KO mice","volume":"33","author":"Burgess","year":"2013","journal-title":"J Neurosci."},{"issue":"2","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0306-4522(02)00089-1","article-title":"Cataplexy-related neurons in the amygdala of the narcoleptic dog","volume":"112","author":"Gulyani","year":"2002","journal-title":"Neuroscience"},{"issue":"33","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"11583","DOI":"10.1523\/JNEUROSCI.0840-15.2015","article-title":"The brain correlates of laugh and cataplexy in childhood narcolepsy","volume":"35","author":"Meletti","year":"2015","journal-title":"J Neurosci"},{"issue":"2","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.neuropharm.2011.10.003","article-title":"Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia","volume":"62","author":"Winrow","year":"2012","journal-title":"Neuropharmacology"},{"issue":"14","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/jm100541c","article-title":"Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia","volume":"53","author":"Cox","year":"2010","journal-title":"J Med Chem"},{"issue":"9","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.5665\/sleep.2080","article-title":"Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy","volume":"35","author":"Andlauer","year":"2012","journal-title":"Sleep"},{"issue":"8","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/sleep\/32.8.993","article-title":"Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy","volume":"32","author":"Thannickal","year":"2009","journal-title":"Sleep"},{"issue":"7725","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41586-018-0540-1","article-title":"T cells in patients with narcolepsy target self-antigens of hypocretin neurons","volume":"562","author":"Latorre","year":"2018","journal-title":"Nature"},{"issue":"5","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/2042098615595359","article-title":"Suvorexant in insomnia: efficacy, safety and place in therapy","volume":"6","author":"Rhyne","year":"2015","journal-title":"Ther Adv Drug Saf"},{"key":"2023031318062063600_","author":"FDA","year":"2014"},{"issue":"48","key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"24353","DOI":"10.1073\/pnas.1907354116","article-title":"Distinct effects of orexin receptor antagonist and GABA A agonist on sleep and physical\/cognitive functions after forced awakening","volume":"116","author":"Seol","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023031318062063600_","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/NSS.S76910","article-title":"Novel class of medications, orexin receptor antagonists, in the treatment of insomnia-critical appraisal of suvorexant","volume":"8","author":"Norman","year":"2016","journal-title":"Nat Sci Sleep"}],"container-title":["Sleep"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsab043\/37115269\/zsab043.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/44\/8\/zsab043\/49518173\/zsab043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/44\/8\/zsab043\/49518173\/zsab043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T16:14:56Z","timestamp":1697904896000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsab043\/6145803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,20]]},"references-count":61,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,2,20]]},"published-print":{"date-parts":[[2021,8,13]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsab043","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,2,20]]},"article-number":"zsab043"}}